Physician

Edgar G Miranda, M.D.

According to 2025 Medicare claims, Edgar Miranda, M.D. (NPI: 1487691655) practices medical oncology in the St. Petersburg-Clearwater-Largo, FL market, with the plurality of this provider's patient population coming from Pinellas, FL. This provider's primary affiliated billing organization is FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC (NPI: 1760590962; TIN: 65-0825133) and primary practice location at 33761-2029.

Miranda's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 831 traditional Medicare patients, billed 197,340 HCPCS/CPT codes, and received $2,274,875 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 908 prescription claims across 188 beneficiaries totaling $2,277,969 in drug costs, led by Revlimid (Lenalidomide). 2015 DME data shows 45 claims. Open Payments data shows 84 records totaling $2,103. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing did not follow a clear longitudinal pattern. Concurrently, Part D prescription costs have risen steadily, from $1,246,920 to $2,277,969. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	666	267,745	$1,607,247
2016	632	229,624	$1,438,081
2017	691	164,798	$1,447,867
2018	641	159,276	$1,260,279
2019	659	163,974	$1,368,488
2020	557	162,979	$1,694,159
2021	498	125,813	$1,464,800
2022	548	148,621	$1,349,828
2023	897	231,239	$2,627,063
2024	831	197,340	$2,274,875

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	127	941	$1,246,920
2016	131	893	$1,214,965
2017	140	742	$1,208,119
2018	134	792	$1,056,438
2019	131	791	$1,035,476
2020	132	1,046	$1,450,365
2021	137	901	$1,243,410
2022	131	819	$1,305,694
2023	180	838	$1,786,056
2024	188	908	$2,277,969

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	45	$1,104
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	290	1,087	$95
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	358	803	$66
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	358	873	$13
36415	Insertion of needle into vein for collection of blood sample	533	1,769	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	567	2,086	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	40	1,099	$668,917
Ibrance	Palbociclib	18	504	$278,894
Jakafi	Ruxolitinib Phosphate	12	360	$201,273
Imbruvica	Ibrutinib	21	624	$194,103
Xarelto	Rivaroxaban	85	3,390	$61,955

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	84	$2,103	PFIZER INC.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Edgar G. Miranda, M.D.?

Tedicare shows public-source Medicare data for Edgar G. Miranda, M.D. (NPI 1487691655), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Edgar G. Miranda, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Edgar G. Miranda, M.D.?

Edgar G. Miranda, M.D. is linked to FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC (billing NPI 1760590962) in the available physician profile data.

Does Edgar G. Miranda, M.D. have Open Payments data?

Edgar G. Miranda, M.D. has 84 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.